Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02122172 · ClinicalTrials.gov registry record · Phase 2
Afatinib in Advanced Refractory Urothelial Cancer
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT02122172 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 32 participants.
The verdict
NCT02122172, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause some of the cells to die.
Interventions
- OTHER laboratory biomarker analysis
- DRUG afatinib dimaleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-09-13 |
| Est. Completion | 2024-04-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02122172
The ClinicalTrials.gov registry entry for NCT02122172 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT02122172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02122172 about?
NCT02122172 is a clinical study titled "Afatinib in Advanced Refractory Urothelial Cancer". This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human...
What is the current status of trial NCT02122172?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2017-09-13. Estimated completion is 2024-04-04.
What interventions are being tested in trial NCT02122172?
The interventions under investigation include: laboratory biomarker analysis (OTHER), afatinib dimaleate (DRUG).
Who is sponsoring clinical trial NCT02122172?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.